# Metagenomi Therapeutics, Inc.: filings

MGX · Nasdaq · CIK 1785279 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mgx.md) · [Financials](/companies/mgx/financials.md) · [Filings](/companies/mgx/filings.md) · [Insiders](/companies/mgx/insiders.md)

## Reports and events: 40 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 58, 8-K 23, 3 15, 10-Q 8, CORRESP 8, D 5, UPLOAD 4, 10-K 3, S-1/A 3, S-8 3, 144 2, ARS 2, DEF 14A 2, DEFA14A 2, DRS/A 2, EFFECT 2, SC 13G 2, SEC STAFF LETTER 2, 424B4 1, 8-A12B 1, CERT 1, DRS 1, DRSLTR 1, S-1 1, S-3 1, SCHEDULE 13G 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-22 | 20:49 ET | [8-K](/filings/0001193125-26-397037.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-397037 |
| 2026-08-10 | 16:12 ET | [10-Q](/filings/0001193125-26-342400.md) | Quarterly report, period 2026-06-30 | 0001193125-26-342400 |
| 2026-08-10 | 16:10 ET | [8-K](/filings/0001193125-26-342388.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-342388 |
| 2026-06-10 | 18:11 ET | [8-K](/filings/0001193125-26-264392.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-26-264392 |
| 2026-05-11 | 16:10 ET | [10-Q](/filings/0001193125-26-216774.md) | Quarterly report, period 2026-03-31 | 0001193125-26-216774 |
| 2026-05-11 | 16:09 ET | [8-K](/filings/0001193125-26-216763.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-216763 |
| 2026-04-27 | 16:55 ET | [DEF 14A](/filings/0001193125-26-182325.md) | Proxy statement, period 2026-04-21 | 0001193125-26-182325 |
| 2026-03-05 | 16:14 ET | [10-K](/filings/0001193125-26-093976.md) | Annual report, period 2025-12-31 | 0001193125-26-093976 |
| 2026-03-05 | 16:09 ET | [8-K](/filings/0001193125-26-093943.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-093943 |
| 2026-01-12 | 09:27 ET | [8-K](/filings/0001193125-26-009928.md) | 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-009928 |
| 2025-11-12 | 08:42 ET | [10-Q](/filings/0001193125-25-276150.md) | Quarterly report, period 2025-09-30 | 0001193125-25-276150 |
| 2025-11-12 | 08:39 ET | [8-K](/filings/0001193125-25-276135.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-276135 |
| 2025-10-01 | 16:47 ET | [8-K](/filings/0001193125-25-226878.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement | 0001193125-25-226878 |
| 2025-08-12 | 16:09 ET | [10-Q](/filings/0000950170-25-107308.md) | Quarterly report, period 2025-06-30 | 0000950170-25-107308 |
| 2025-08-12 | 16:07 ET | [8-K](/filings/0000950170-25-107304.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-107304 |
| 2025-06-11 | 18:20 ET | [8-K](/filings/0000950170-25-084529.md) | 5.07 Shareholder vote results | 0000950170-25-084529 |
| 2025-05-14 | 07:15 ET | [8-K](/filings/0000950170-25-070906.md) | 8.01 Other events | 0000950170-25-070906 |
| 2025-05-13 | 16:40 ET | [10-Q](/filings/0000950170-25-070463.md) | Quarterly report, period 2025-03-31 | 0000950170-25-070463 |
| 2025-05-13 | 16:35 ET | [8-K](/filings/0000950170-25-070448.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-070448 |
| 2025-04-28 | 16:01 ET | [DEF 14A](/filings/0000950170-25-059276.md) | Proxy statement, period 2025-04-25 | 0000950170-25-059276 |
| 2025-03-17 | 17:01 ET | [8-K](/filings/0000950170-25-040453.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-25-040453 |
| 2025-03-17 | 16:06 ET | [8-K](/filings/0000950170-25-040238.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-040238 |
| 2025-03-17 | 16:01 ET | [10-K](/filings/0000950170-25-040217.md) | Annual report, period 2024-12-31 | 0000950170-25-040217 |
| 2025-01-16 | 08:59 ET | [8-K](/filings/0000950170-25-006028.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-006028 |
| 2024-12-10 | 21:22 ET | [8-K](/filings/0000950170-24-134733.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-134733 |
| 2024-11-13 | 16:07 ET | [8-K](/filings/0000950170-24-126317.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-126317 |
| 2024-11-13 | 16:01 ET | [10-Q](/filings/0000950170-24-126273.md) | Quarterly report, period 2024-09-30 | 0000950170-24-126273 |
| 2024-09-03 | 16:09 ET | [8-K](/filings/0000950170-24-102805.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-102805 |
| 2024-08-14 | 08:18 ET | [8-K](/filings/0000950170-24-096673.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-096673 |
| 2024-08-14 | 08:00 ET | [10-Q](/filings/0000950170-24-096665.md) | Quarterly report, period 2024-06-30 | 0000950170-24-096665 |
| 2024-05-14 | 16:08 ET | [8-K](/filings/0000950170-24-059532.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-059532 |
| 2024-05-14 | 16:04 ET | [10-Q](/filings/0000950170-24-059504.md) | Quarterly report, period 2024-03-31 | 0000950170-24-059504 |
| 2024-05-01 | 16:01 ET | [8-K](/filings/0000950170-24-051238.md) | 1.02 Termination of a material agreement; 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-051238 |
| 2024-03-27 | 09:23 ET | [8-K](/filings/0000950170-24-036847.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-036847 |
| 2024-03-27 | 08:44 ET | [10-K](/filings/0000950170-24-036838.md) | Annual report, period 2023-12-31 | 0000950170-24-036838 |
| 2024-02-13 | 16:06 ET | [8-K](/filings/0001193125-24-033697.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-24-033697 |
| 2024-02-07 | 16:07 ET | [S-1/A](/filings/0001193125-24-026662.md) | Registration statement, amended | 0001193125-24-026662 |
| 2024-02-05 | 06:11 ET | [S-1/A](/filings/0001193125-24-023377.md) | Registration statement, amended | 0001193125-24-023377 |
| 2024-01-08 | 06:08 ET | [S-1/A](/filings/0001193125-24-003810.md) | Registration statement, amended | 0001193125-24-003810 |
| 2024-01-05 | 17:16 ET | [S-1](/filings/0001193125-24-003477.md) | Registration statement | 0001193125-24-003477 |

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.